TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04694807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Cognitive Behavioural Therapy for Complicated Grief Reactions
Description: CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 2.25 hours for the group format.~Group-based CBTgrief will follow the same content and exercises for each session as individually delivered CBTgrief.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individually delivered Cognitive Behavioural Therapy for Complicated Grief Reactions
Description: CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 1 hour for the individually delivered format.~Individually delivered CBTgrief will follow the same content and exercises for each session as group-based CBTgrief.
Study: NCT04874337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.
Description: The subjects for the training program were prepared by the researchers by scanning the relevant literature. In particular, the ICN Framework of Disaster Nursing Competencies developed by the International Nurses Association (ICN) and the World Health Organization (WHO), the second is the universal standards that should be fundamental in nursing and midwifery education (Global Standards for the Initial Education of Professional Nurses and Midwives). The training program was conducted both theoretically and practically. The theoretical section is based on Jenning's disaster nursing management model. Investigator is a First and Emergency Aid instructor. In addition, support was received from an experienced psychologist and AFAD trainers who provided support to the victims of the Izmir earthquake during the training process. In this context, an 8-module training program was created.
Study: NCT05111366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsules
Description: Anlotinib Hydrochloride is a capsule in the form of 8 mg,10 mg, and 12 mg, orally, once daily, 2 weeks on/1 week off.
Study: NCT04748705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-1
Description: Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID Tablet
Description: Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
Study: NCT06291831

Intervention type: OTHER
Intervention: Controls
Description: Patients who do not receive Nirmatrevir/ritonavir (Paxlovid)
Study: NCT05014945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (atelocollagen group)
Description: Epidural nerve block and atelocollagen injection into the multifidus muscle were performed sequentially. The target level is determined by the clinician by combining the pre-MRI and the patient's symptoms. All procedures are performed under the guidance of fluroscopy. For epidural nerve block, use 10cc of 0.9% normal saline mixed with 3000IU of hyaluronidase to be injected. After the epidural nerve block, a solution of 1 mL of atelocollagen mixed with 1 mL of 1% lidocaine is injected into the multifidus muscle to complete the entire procedure.
Study: NCT05984225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online learning
Description: The students performed a 10-week Online Learning (OL) program based on Professional Ethics. The program included:~1. Synchronous learning (1 session/week, 1 hour each).~2. Asynchronous learning: i) OL classes were recorded; ii) Moodle platform: for read breaking news, upload tasks or solve any doubt they may have through discussion forums; iii) An OL specific syllabus that consisted of five themes from the ethics knowledge; iv) An OL glossary, including the concept, explanation of the concept, and source; v) Bullet-point videos highlighting the most important issues of each theme; vi) Podcasts about Professional Ethics, Ethics in physiotherapy; vii) Links to websites; viii) Gamification using mobile Apps regarding ethical decision-making, healthcare, and Ethics or Professional Ethics, as well as an OL crossword; ix) OL activities were created and personalized comments about the activities were reported by the teachers to give feedback to the students.
Study: NCT06087965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5mg/day oral fingolimod over a course of 3 consecutive days
Study: NCT04590495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300 mg Cannabidiol (CBD) oil
Description: Participant will either be given a 300mg dosage of CBD oil. After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant will either be given a placebo . After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
Study: NCT06331793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active AlgoCare
Description: Device that emits Pulsed Electromagnetic Fields

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-active AlgoCare
Description: Device that doesn't emit Pulsed Electromagnetic Fields
Study: NCT05689645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F573 for injection
Description: The first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg,2 mL,intramuscular injection (IM),once a day for 7 daysand. the subsequent 9 patients with CHB were given doses of 2 mL intramuscular injection (IM), once a day for 7 days, according to the results of the efficacy and safety trials of the first 16 patients. The dose of the second stage was determined according to the results of the efficacy and safety trials in the first stage. The dose volume was 2 mL, and was administered intramuscular injection (IM) once a day for 14 days. The dosage of the third stage was determined according to the results of the first and second stage efficacy and safety trials. The dosage volume was 2 mL and intramuscular injection (IM) was administered once a day for 28 consecutive days. The dosage of the above three stages of administration was calculated according to the weight of the most recent visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterilizing water for injection
Description: The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection.~Medication course: The first stages were administered once a day for 7 days and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days.
Study: NCT05281809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
Description: This protocol describes the use of an automated cell processor and culture system, the CliniMACS Prodigy device sold by Miltenyi Biotec, for the local manufacture of CAR T-cells targeting the CD19 antigen. The manufacturing process will use a lentiviral vector (CAR19) provided by Lentigen, a wholly owned subsidiary of Miltenyi Biotec, to transfect T-cells collected from eligible patients. Live cells will be harvested by the device after culture and infused intravenously to the patient from whom the cells were originally obtained.
Study: NCT06296303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic therapy
Description: Pulsed etromagnetic therapy (1000 gauss) on sciatic nerve in gluteal fold. ( 30 min )

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound phonophoresis
Description: Phonophoresis using dexamethasone and topical diclofenac sodium gel on sciatic nerve in subgluteal fold and mid thigh

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional physical therapy consisting of~1. IF current on lumbar spine. (15 min )~2. Hotpack on lumbar spine . (15 min )~3. Neurodynamic mobilization .~4. Mobilization and manipulation for lumbar spine.~5. Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: Conventional physical therapy consisting of~1. IF current on lumbar spine. (15 min )~2. Hotpack on lumbar spine . (15 min )~3. Neurodynamic mobilization .~4. Mobilization and manipulation for lumbar spine.~5. Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: Conventional physical therapy consisting of~1. IF current on lumbar spine. (15 min )~2. Hotpack on lumbar spine . (15 min )~3. Neurodynamic mobilization .~4. Mobilization and manipulation for lumbar spine.~5. Exercises
Study: NCT05982535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easy Dew MD Regen Cream
Description: The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Easy Dew MD Regen Cream
Description: The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
Study: NCT04862507

Intervention type: OTHER
Intervention: Telephone call on day 90
Description: telephone call on day 90 to assess the primary outcome (mRs 90)
Study: NCT06209099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonoperative Management (NOM)
Description: Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Nonoperative Management (NOM)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Excision (LE)
Description: Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Local Excision (LE)
Study: NCT04862507

Intervention type: OTHER
Intervention: Telephone call on day 90
Description: telephone call on day 90 to assess the primary outcome (mRs 90)

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantification of lesion water uptake by CT densitometry
Description: Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantification of lesion water uptake by CT densitometry
Description: Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging
Study: NCT05088122

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, not applicable
Study: NCT06209099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision (TME)
Description: Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Total Mesorectal Excision (TME)
Study: NCT04790682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.
Description: * At pre-screening NGS analysis on tumor tissue (slides). Only patients with at least 1 mutation at NGS on the tumor tissue will ultimately be enrolled in the main study, to have the possibility to follow the mutation using ctDNA.~* Main study will be initiated after results of the NGS and before initiation of pembrolizumab. Blood specimens will be taken with EDTA tubes or streck tubes at the time of puncture for pembrolizumab infusion at baseline before starting treatment, at 3 weeks, 6 weeks and then every 6 weeks (30 ml at Baseline then 20 ml of blood). Blood immunomonitoring will be done before starting the treatment, at 6 weeks and at 18 Week. An additional measurement will be performed if treatment is stopped before the end of the study (18 ml of blood).~* Optional blood samples will be realized to analyse the degree of activity of the plasmatic lymphocytes before starting the treatment and at 6 weeks and (18 ml of blood).
Study: NCT05712954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music group
Description: music

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video group
Description: video
Study: NCT05018078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coronavirus vaccine
Description: Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
Study: NCT06060587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 via IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: Prior to randomization as part of standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Prior to randomization as part of standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: 1000 mg by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: 1000 mg by mouth
Study: NCT05545839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition coaching
Description: Transition coaching sessions (8 sessions), covering paediatric to adult care, self-advocacy, medication management, general health, lifestyle and behaviours, future planning, screening for mood disorders and coping skills.
Study: NCT05150717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Jaktinib
Description: Subjects will receive single dose of orally \[14C\]-Jaktinib on Day 1.
Study: NCT05731518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0245
Description: SC0245 Quaque Die(QD) administered with a 3-day on and 4-day off schedule in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
Study: NCT05947656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviFUS System
Description: NaviFUS System (Neuronavigation-Guided Focused Ultrasound System) is a new non-invasive device, which uses the neuronavigation principle to guide focused ultrasound (FUS) energy precisely delivering through the skull to selected brain tissues without surgery in real-time. In this clinical study, the NaviFUS System is intended to deliver low intensity FUS to generate neuromodulation effects on a predetermined treatment region (one or both of the hippocampi which are associated with seizure), for the treatment for drug-resistant temporal lobe epilepsy (TLE).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviFUS System
Description: NaviFUS System (Neuronavigation-Guided Focused Ultrasound System) is a new non-invasive device, which uses the neuronavigation principle to guide focused ultrasound (FUS) energy precisely delivering through the skull to selected brain tissues without surgery in real-time. In this clinical study, the NaviFUS System is intended to deliver low intensity FUS to generate neuromodulation effects on a predetermined treatment region (one or both of the hippocampi which are associated with seizure), for the treatment for drug-resistant temporal lobe epilepsy (TLE).
Study: NCT06316076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-DNT cells
Description: Lentiviral vector-transduced DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
Study: NCT05789563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia and Smartwatch model
Description: Breathing mixtures of O2 (14 %, 12 %, 10 %) balanced with N2 and monitoring SpO2 by one of the smartwatch models on left wrist and by pulse oximeter on left index finger.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia and Smartwatch model
Description: Breathing mixtures of O2 (14 %, 12 %, 10 %) balanced with N2 and monitoring SpO2 by one of the smartwatch models on left wrist and by pulse oximeter on left index finger.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia and Smartwatch model
Description: Breathing mixtures of O2 (14 %, 12 %, 10 %) balanced with N2 and monitoring SpO2 by one of the smartwatch models on left wrist and by pulse oximeter on left index finger.
Study: NCT05498467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: 100 mg Anakinra injections s.c.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/ml Injection
Description: 9 mg Sodium Chloride injections s.c.
Study: NCT05731518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 80mg/m\^2 via IV administered for every 4 weeks (fixed dosing) in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
Study: NCT05357508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention brochure
Description: Provide participants with information about their personalized risk for colorectal cancer and appropriate screening recommendations to facilitate their screening option choice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control brochure
Description: Provide participants with general information about options for colorectal cancer screening.
Study: NCT06508515

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unadapted Research Units in Behavioral Intervention (RUBI) implementation strategy
Description: The unadapted RUBI IS involves weekly, one hour educational meetings where sessions involve discussion of homework from the week prior (5 minutes), didactic instruction on targeted behavioral strategies (40 minutes), coaching and consultation around the newly learned strategy (10 minutes), and fidelity review, where RUBI implementation is observed (5 minutes). Finally, Attend\| Behavior® is a HIPAA-compliant mobile application support that is designed to support RUBI delivery and implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RUBI in Educational Settings (RUBIES)-Team
Description: RUBIES is an 8-module intervention that provides educators a range of skills to support the building of a behavioral management toolbox to be used, as needed, with autistic children and disruptive behavior. The program emphasizes: 1) tailoring the intervention to the specific child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice; 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to modify behaviors. All educators will receive RUBIES training across 24 weeks via Zoom.
Study: NCT05152576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA X
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA X
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA X
Description: Intramuscular Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injection
Study: NCT06060054

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Device measurements
Description: Overnight device measurements

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Device measurements
Description: Overnight device measurements
Study: NCT05271760

Intervention type: PROCEDURE
Intervention: Single-shot spinal analgesia
Description: The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml

Intervention type: PROCEDURE
Intervention: Continuous epidural analgesia
Description: Epidural analgesia is performed using a 16-gauge Tuohy epidural needle using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid a test dose of 3 ml lidocaine 1.5% with epinephrine 1:200000 will be given via inserted catheter, 10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse in a rate of 6 -14 ml/h.
Study: NCT06041594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laguna Thrombectomy System
Description: Removal of clot using the Laguna Thrombectomy System to treat Pulmonary Embolism
Study: NCT05271760

Intervention type: PROCEDURE
Intervention: Combined spinal-epidural analgesia
Description: Epidural analgesia is performed using a combined spinal-epidural set. using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance, once epidural space will be detected, 27 G Whitacre spinal needle inserted through Touhy epidural needle, intrathecal injection of 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml. Then an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid.~10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse at a rate of 6 -14 ml/h if needed.